In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on OncoSec Medical (NASDAQ: ONCS), with a price target of $4. The company’s shares closed yesterday at $1.34.
Selvaraju noted:
“We note that Ms. O’Connor, know one another well from their time at Lilly & Co. (LLY; not rated) in 2008—and thus this executive appointment appears to demonstrate Mr. O’Connor’s continued progress towards enhancing the leadership team at OncoSec. Ms. Bonstein joins OncoSec from Advaxis, where she served as Vice President. Prior to Advaxis, she held key financial leadership positions with Eli Lilly & Johnson & Johnson (JNJ; not rated). Ms. Bonstein holds a B.S. in finance from an M.B.A. from Rider University and is a graduate of Johnson & Development Program. She possesses extensive experience in leading biotech firms. While at Lilly, Ms.”
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 1.2% and a 44.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for OncoSec Medical with a $4.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.95 and a one-year low of $0.88. Currently, OncoSec Medical has an average volume of 646.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OncoSec Medical, Inc. engages in the design and commercialize medical products for the treatment of cancer. It involves in the discovery and development of novel immunotherapeutic products to improve treatment options for patients and physicians, which intends to treat oncology indications.
